Aims & Scope

The Journal of Hematology and Oncology Research (JHOR) publishes high-quality research across the full spectrum of hematology and oncology, including basic, translational, clinical, and diagnostic studies that advance understanding and treatment of blood disorders and cancer.

Hematology Research Oncology Research Translational Studies Clinical Investigations Molecular Pathogenesis

Scope Focus: We welcome studies that advance knowledge in hematology and oncology through mechanistic insights, clinical observations, translational applications, or diagnostic innovation. All submissions should contribute meaningfully to understanding disease biology or improving patient outcomes.

The Journal of Hematology and Oncology Research (JHOR) publishes high-impact research across hematology and oncology, encompassing basic science, translational studies, clinical investigations, and diagnostic innovations. The journal serves as a platform for discoveries that deepen understanding of blood disorders and cancer, improve disease classification, and inform therapeutic development.

We welcome original research on molecular pathophysiology, tumor biology, immune mechanisms, hematopoiesis, and disease modeling, as well as translational and clinical studies that bridge laboratory findings with patient care. Research using patient samples, omics technologies, cellular systems, animal models, and clinical datasets is encouraged, provided it advances scientific or clinical knowledge in the field.

Clinical, pathological, and diagnostic studies are within scope when they provide novel insights into disease mechanisms, identify new therapeutic targets, or demonstrate clinical relevance of biological findings. Case reports are considered when they describe rare presentations, novel therapeutic responses, or unique biological insights.

Article types include original research, reviews, methods and protocols, short communications, data notes, case reports, and commentaries. JHOR serves researchers, clinicians, and scientists in hematology, oncology, translational medicine, and related disciplines.

Core Research Domains

●

Molecular Oncology

Cancer genomics and epigenetic modifications in tumorigenesis
Signal transduction pathways driving malignant transformation
Tumor microenvironment interactions and cellular crosstalk
Cancer stem cell biology and self-renewal mechanisms
Molecular basis of metastasis and invasion
Oncogene and tumor suppressor gene function

Typical Fit Example: Identification of novel signaling pathways regulating epithelial-mesenchymal transition in breast cancer cells, with validation using CRISPR-Cas9 gene editing and pathway inhibitor studies.

●

Hematological Pathophysiology

Molecular mechanisms of hematopoiesis and lineage commitment
Pathogenesis of leukemias and lymphomas at cellular level
Genetic and epigenetic drivers of hematologic malignancies
Molecular basis of hemolytic anemias and coagulopathies
Platelet and leukocyte dysfunction mechanisms
Stem cell biology and bone marrow microenvironment

Typical Fit Example: Investigation of JAK2 V617F mutation effects on megakaryocyte differentiation and platelet production in myeloproliferative neoplasms using patient-derived cells and mouse models.

●

Cancer Immunology

Tumor-immune system interactions and immune evasion mechanisms
Molecular basis of immune checkpoint regulation
T cell exhaustion and dysfunction in tumor microenvironment
Antigen presentation and recognition pathways in cancer
Innate immune responses to malignant cells
Immunosuppressive mechanisms in tumor progression

Typical Fit Example: Molecular characterization of PD-L1 upregulation mechanisms in melanoma cells under hypoxic conditions, including transcriptional regulation and post-translational modifications.

●

Biomarkers & Molecular Diagnostics

Discovery and validation of disease-specific biomarkers
Molecular signatures for disease classification and prognosis
Circulating tumor markers and liquid biopsy analytes
Genetic and proteomic profiling for disease stratification
Molecular mechanisms underlying biomarker expression
Novel diagnostic targets in hematologic and oncologic diseases

Typical Fit Example: Identification of circulating microRNA signatures associated with acute myeloid leukemia progression, with studies linking miRNA expression to leukemogenesis pathways.

Secondary Focus Areas

Pharmacogenetics & Drug Mechanisms

Molecular mechanisms of drug resistance, pharmacogenomic determinants of treatment response, and cellular pathways mediating chemoresistance in hematologic and oncologic diseases.

Disease Modeling Systems

Development and validation of cellular and animal models recapitulating disease pathophysiology, including patient-derived xenografts, organoids, and genetically engineered models.

Molecular Cytogenetics

Chromosomal abnormalities and structural variants in hematologic malignancies and solid tumors, including mechanisms of chromosomal instability and DNA damage responses.

Tumor Metabolism

Metabolic reprogramming in cancer cells, metabolic dependencies of malignant cells, and metabolic interactions within the tumor microenvironment.

Molecular Mechanisms of Angiogenesis

Vascular development in tumors, pro-angiogenic signaling pathways, and molecular regulators of tumor blood vessel formation and function.

Hereditary Cancer Genetics

Germline mutations predisposing to hematologic and oncologic diseases, molecular mechanisms of inherited cancer syndromes, and genotype-phenotype correlations.

Emerging Research Areas

Encouraged with Scientific Merit

The following areas are actively encouraged when they contribute novel insights to hematology or oncology. Submissions undergo standard editorial review with attention to scientific rigor and relevance.

AI-Driven Molecular Analysis: Machine learning approaches for identifying disease mechanisms, pathway analysis, and molecular pattern recognition in omics datasets.

Single-Cell Mechanistic Studies: Single-cell genomics, transcriptomics, and proteomics revealing cellular heterogeneity and clonal evolution in disease.

Epigenetic Regulation: DNA methylation, histone modifications, and chromatin remodeling mechanisms in hematologic and oncologic pathogenesis.

Extracellular Vesicle Biology: Molecular cargo and signaling mechanisms of exosomes and microvesicles in disease progression and cell-cell communication.

Molecular Imaging Biomarkers: Novel imaging agents and techniques for visualizing disease processes at molecular and cellular levels.

Molecular Mechanisms in Rare Cancers: Pathophysiological mechanisms of uncommon malignancies with unique molecular features.

Article Types & Editorial Priorities

Priority 1

Fast-Track Review

Original Research Articles Systematic Reviews & Meta-Analyses Methods & Protocols Translational Studies

Priority 2

Standard Review

Short Communications Data Notes Perspectives Technical Notes

Occasionally Accepted

Selective Acceptance

Case Reports (with novel insight) Opinion Pieces (by invitation) Commentaries

Editorial Standards & Requirements

Reporting Guidelines

ARRIVE guidelines for animal studies
MIQE for qPCR experiments
PRISMA for systematic reviews
REMARK for biomarker studies
STARD for diagnostic accuracy

Data Transparency

Raw data deposition in public repositories
Genomic data in GEO or ArrayExpress
Proteomic data in PRIDE or ProteomeXchange
Code availability for computational analyses
Materials and reagent sharing statements

Ethics & Integrity

IRB/Ethics committee approval for human samples
IACUC approval for animal experiments
Informed consent documentation
Conflict of interest disclosure
Adherence to COPE guidelines

Preprint Policy

Preprints on bioRxiv, medRxiv accepted
Must disclose preprint DOI at submission
Preprint posting does not affect consideration
Final version must acknowledge preprint
Preprint servers must be non-commercial

Journal of Hematology and Oncology Research

Journal of Hematology and Oncology Research – Aim And Scope

Aims & Scope